Clear Program Physician Webpage
Information specifically for physicians to help your patient understand PAD. Learn More »
Take a Stand Against CLTI for Your Patients
Choose the new standard of care for BTK treatment that delivers superior results without compromising safety.
Chronic Limb-Threatening Ischemia (CLTI) is a severe form of peripheral artery disease (PAD) that can lead to amputation and increased mortality/cardiovascular events.1 Now, Abbott's Esprit BTK System offers a breakthrough innovation for you and your patients as the first-and-only FDA-approved drug-eluting resorbable scaffold for CLTI. The only BTK device that does it all:
- Provides scaffolding to address vessel recoil and dissection,2 with radial strength similar to a metallic stent within the first 6 months3
- Delivers drug via everolimus elution to minimize neointimal hyperplasia2,4
- Fully resorbable, preserving future treatment options5
Deliver superior results for your patients without compromising their safety
Low Reintervention Rate in CLTI Patients
90% of patients treated with Esprit BTK did not require a reintervention through 3 years.8*
Superior Efficacy at 1 year6, Sustained Benefits through 3 years8
31% improvement in limb salvage and primary patency at 1 year6, with sustained benefits through 3 years.8
"The durability of this result has never been demonstrated with any BTK technology previously."
-Sahil Parikh, MD, New York-Presbyterian/Columbia University Irving Medical Center
The LIFE-BTK Study, published in the New England Journal of Medicine, is the first successful RCT to demonstrate superiority of an interventional device over standard of care for treatment of BTK disease in CLTI patients.6 The 3-year data demonstrated sustained efficacy and safety.8
Take BTK Treatment in Stride with State-of-the-Art Care
Watch how the Esprit™ BTK System does it all for CLTI: addressing vessel recoil and dissection,2 combined with a drug to inhibit neointimal hyperplasia,4 and then fully resorbs over time,5 preserving future treatment options.
Case Studies: A Giant Step Forward in BTK Treatment
Physicians share their experience with the Esprit™ BTK System and the advantages it delivers in treating their patients and improving outcomes.
Sharing Information, Promoting Understanding:
Resources to Help Your Patients Walk Away from PAD/CLTI
Beyond the treatment, make sure your referring physicians are fully aware of PAD and CLTI and how they can help with early diagnosis and timely treatment. For information specifically for the physician, visit our Clear Program webpage. Access a full range of helpful tools and insights.
CE Mark Rapid Exchange (RX):
| Diameter | 18 | 28 | 38 | Sheath (F) | Maximum Post-Dilation Diameter | Nominal/RBP Inflation Pressure |
|---|---|---|---|---|---|---|
| 2.5 mm | 1204250-18 | 1204250-28 | 1204250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
| 3.0 mm | 1204300-18 | 1204300-28 | 1204300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
| 3.5 mm | 1204350-18 | 1204350-28 | 1204350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
| 3.75 mm | 1204375-18 | 1204375-28 | 1204375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
FDA Over-the-wire (OTW)
| Diameter | 18 | 28 | 38 | Sheath (F) | Maximum Post-Dilation Diameter | Nominal/RBP Inflation Pressure |
|---|---|---|---|---|---|---|
| 2.5 mm | 1212250-18 | 1212250-28 | 1212250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
| 3.0 mm | 1212300-18 | 1212300-28 | 1212300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
| 3.5 mm | 1212350-18 | 1212350-28 | 1212350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
| 3.75 mm | 1212375-18 | 1212375-28 | 1212375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
FDA Rapid Exchange (RX)
| Diameter | 18 | 28 | 38 | Sheath (F)4 | Maximum Post-Dilation Diameter4 | Nominal/RBP Inflation Pressure4 |
|---|---|---|---|---|---|---|
| 2.5 mm | 1203250-18 | 1203250-28 | 1203250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
| 3.0 mm | 1203300-18 | 1203300-28 | 1203300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
| 3.5 mm | 1203350-18 | 1203350-28 | 1203350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
| 3.75 mm | 1203375-18 | 1203375-28 | 1203375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
This device is commercially available for use in select international markets. Check the regulatory status in your geography.
References
*Reintervention defined as CD-TLR
- Farber, A., Menard, M. T., Bonaca, M. P., Bradbury, A., Conte, M. S., Debus, E. S., ... & Rosenfield, K. (2024). BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischemia globally. British Journal of Surgery, 111(2), znad413.
- Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU). Refer to IFU for additional information.
- Data on file at Abbott. Testing done with XIENCE Sierra™ Stent 3.5 x 38 mm at nominal.
- Data on file at Abbott.
- Data on file at Abbott. Excluding platinum markers.
- Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Eng J Med 2024;390:9-19.
- Brian G. DeRubertis et al., Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK. Circulation 2025.
- Parikh, S., Three-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, Presented at TCT 2025.
MAT-2405960 v7.0